Last reviewed · How we verify
VPRIV
VPRIV, marketed by Shaare Zedek Medical Center, is a therapeutic agent with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established position. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | VPRIV |
|---|---|
| Also known as | Velaglucerase Alfa, velaglucerase alfa, Gene-Activated® Human Glucocerebrosidase(GA-GCB) |
| Sponsor | Shaare Zedek Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Survey Study for Velaglucerase Alfa (VPRIV) in Japan
- A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease (PHASE3)
- A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion
- A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease
- A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
- A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy (PHASE4)
- An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 (PHASE2, PHASE3)
- Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |